ZK-93426
From Self-sufficiency
| ZK-93426 | |
|---|---|
| File:ZK-93426 structure.png | |
| ethyl 5-isopropoxy-4-methyl-9H-β-carboline-3-carboxylate | |
| Other names ZK-93426; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-b]indole-3-carboxylate | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 89592-45-0 |
| PubChem | 115210 |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C18H20N2O3 |
| Molar mass | 314.336 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
ZK-93426 (ethyl-5-isopropoxy-4-methyl-beta-carboline-3-carboxylate) is a drug from the beta-carboline family. It acts as a weak partial inverse agonist of benzodiazepine receptors,[1] meaning that it causes the opposite effects to the benzodiazepine class of drugs and has anxiogenic properties,[2] although unlike most benzodiazepine antagonists it is not a convulsant and actually has weak anticonvulsant effects.[3] In human tests it produced alertness, restlessness and feelings of apprehension, and reversed the effect of the benzodiazepine lormetazepam.[4][5] It was also shown to produce nootropic effects[6][7] and increased release of acetylcholine.[8][9]
See also
References
- ↑ Camerman A, Mastropaolo D, Hempel A, Camerman N. Ethyl 5-isopropoxy-4-methyl-beta-carboline-3-carboxylate: structural determinants of benzodiazepine-receptor antagonism. Acta Crystallographica Section C. 2005 Apr;61(Pt 4):o265-6. PMID 15805647
- ↑ File SE, Pellow S, Jensen LH. Actions of the beta-carboline ZK 93426 in an animal test of anxiety and the holeboard: interactions with Ro 15-1788. Journal of Neural Transmission. 1986;65(2):103-14. PMID 3009709
- ↑ Jensen LH, Petersen EN, Braestrup C, Honoré T, Kehr W, Stephens DN, Schneider H, Seidelmann D, Schmiechen R. Evaluation of the beta-carboline ZK 93 426 as a benzodiazepine receptor antagonist. Psychopharmacology (Berlin). 1984;83(3):249-56. PMID 6089247
- ↑ Dorow R, Duka T, Höller L, Sauerbrey N. Clinical perspectives of beta-carbolines from first studies in humans. Brain Research Bulletin. 1987 Sep;19(3):319-26. PMID 2890423
- ↑ Duka T, Goerke D, Dorow R, Höller L, Fichte K. Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93 426: antagonism of lormetazepam's psychotropic effects. Psychopharmacology (Berlin). 1988;95(4):463-71. PMID 2905500
- ↑ Duka T, Edelmann V, Schütt B, Dorow R. Beta-carbolines as tools in memory research: human data with the beta-carboline ZK 93426. Psychopharmacol Series. 1988;6:246-60. PMID 3064085
- ↑ Duka T, Ott H, Rohloff A, Voet B. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacology (Berlin). 1996 Feb;123(4):361-73. PMID 8867876
- ↑ Moore H, Sarter M, Bruno JP. Age-dependent modulation of in vivo cortical acetylcholine release by benzodiazepine receptor ligands. Brain Research. 1992 Nov 20;596(1-2):17-29. PMID 1334777
- ↑ Moore H, Sarter M, Bruno JP. Bidirectional modulation of stimulated cortical acetylcholine release by benzodiazepine receptor ligands. Brain Research. 1993 Nov 12;627(2):267-74. PMID 8298971
| 35px | This drug article relating to the nervous system is a stub. You can help ssf by expanding it. |
